Blocking ZEB1 reverses chemoimmunotherapy resistance in pancreatic cancer by boosting CD8+ T cells, reducing neutrophils, and enhancing tumor-killing immune responses. This evidence concerns the gene ZEB1 and pancreatic neoplasm.